{"version":"1.0","provider_name":"FH Australasia Network","provider_url":"https:\/\/www.athero.org.au\/fh","title":"National FH Registry newsletter \u2013 November 2018 - FH Australasia Network","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"KSSuMxYuOy\"><a href=\"https:\/\/www.athero.org.au\/fh\/2925-2\/\">National FH Registry newsletter \u2013 November 2018<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.athero.org.au\/fh\/2925-2\/embed\/#?secret=KSSuMxYuOy\" width=\"600\" height=\"338\" title=\"&#8220;National FH Registry newsletter \u2013 November 2018&#8221; &#8212; FH Australasia Network\" data-secret=\"KSSuMxYuOy\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";var e=!1,o=!1;if(l.querySelector)if(d.addEventListener)e=!0;if(d.wp=d.wp||{},!d.wp.receiveEmbedMessage)if(d.wp.receiveEmbedMessage=function(e){var t=e.data;if(t)if(t.secret||t.message||t.value)if(!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var r,a,i,s=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),n=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),o=new RegExp(\"^https?:$\",\"i\"),c=0;c<n.length;c++)n[c].style.display=\"none\";for(c=0;c<s.length;c++)if(r=s[c],e.source===r.contentWindow){if(r.removeAttribute(\"style\"),\"height\"===t.message){if(1e3<(i=parseInt(t.value,10)))i=1e3;else if(~~i<200)i=200;r.height=i}if(\"link\"===t.message)if(a=l.createElement(\"a\"),i=l.createElement(\"a\"),a.href=r.getAttribute(\"src\"),i.href=t.value,o.test(i.protocol))if(i.host===a.host)if(l.activeElement===r)d.top.location.href=t.value}}},e)d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",t,!1),d.addEventListener(\"load\",t,!1);function t(){if(!o){o=!0;for(var e,t,r,a=-1!==navigator.appVersion.indexOf(\"MSIE 10\"),i=!!navigator.userAgent.match(\/Trident.*rv:11\\.\/),s=l.querySelectorAll(\"iframe.wp-embedded-content\"),n=0;n<s.length;n++){if(!(r=(t=s[n]).getAttribute(\"data-secret\")))r=Math.random().toString(36).substr(2,10),t.src+=\"#?secret=\"+r,t.setAttribute(\"data-secret\",r);if(a||i)(e=t.cloneNode(!0)).removeAttribute(\"security\"),t.parentNode.replaceChild(e,t);t.contentWindow.postMessage({message:\"ready\",secret:r},\"*\")}}}}(window,document);\n<\/script>\n","description":"&nbsp; November\u00a02018 \u00a0 \u00a0BROADER ACCESS TO PCSK9 INHIBITORS FOR FH PATIENTS\u00a0 \u00a0 PCSK9 inhibitor medication is now supported by the Pharmaceutical Benefits Scheme (PBS) for patients with heterozygous FH\u00a0\u00a0who need additional help to lower their LDL-Cholesterol levels. Sold under the trade name Repatha, the medication called evolocumab will now be more accessible to patients with &hellip; Continue reading","thumbnail_url":"https:\/\/www.athero.org.au\/fh\/wp-content\/uploads\/line-1.jpg"}